GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults

Lanini S, Capone S, Antinori A, Milleri S, Nicastri E, Camerini R, Agrati C, Castilletti C, Mori F, Sacchi A, Matusali G, Gagliardini R, Ammendola V, Cimini E, Grazioli F, Scorzolini L, Napolitano F, Piazzi MM, Soriani M, De Luca A, Battella S, Sommella A, Contino AM, Barra F, Gentile M, Raggioli A, Shi Y, Girardi E, Maeurer M, Capobianchi MR, Vaia F, Piacentini M, Kroemer G, Vitelli A, Colloca S, Folgori A, Ippolito G

medRxiv - (-) - [2021-04-13; online 2021-04-13]

Category: Biochemistry

Category: Drug Discovery

Type: Preprint

DOI 10.1101/2021.04.10.21255202

Crossref 10.1101/2021.04.10.21255202

ClinicalTrials.gov: NCT04528641 Cinical trials of GRAd-COV2, a vaccine candidate based on an adenoviral vector derived from a group C Gorilla adenovirus